Finding new treatments targeting cancer stem cells (CSCs) within a tumor seems to be critical to halt cancer and improve patient survival. Osteosarcoma is an aggressive tumor affecting adolescents, for which there is no second-line chemotherapy. Uncovering new molecular mechanisms underlying the development of osteosarcoma and origin of CSCs is crucial to identify new possible therapeutic strategies. Here, we aimed to characterize genetically and molecularly the human osteosarcoma 3AB-OS CSC line, previously selected from MG63 cells and which proved to have both in vitro and in vivo features of CSCs. Classic cytogenetic studies demonstrated that 3AB-OS cells have hypertriploid karyotype with 71\u201382 chromosomes. By comparing 3AB-OS CSCs ...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can hal...
open10siThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program...
Finding new treatments targeting cancer stem cells (CSCs) within a tumor seems to be critical to hal...
Cancer Stem Cells (CSCs) are thought to be the cause of cancer initiation, growth and development. T...
Osteosarcoma (OSA) is the most common primary malignant bone tumor, usually arising in the long bone...
Cancer Stem Cells (CSCs) are thought to be the cause of cancer initiation, growth and development. T...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can hal...
open10siThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program...
Osteosarcoma (OS) is the most common type of bone cancer, with a peak incidence in the early childho...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can hal...
open10siThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program...
Finding new treatments targeting cancer stem cells (CSCs) within a tumor seems to be critical to hal...
Cancer Stem Cells (CSCs) are thought to be the cause of cancer initiation, growth and development. T...
Osteosarcoma (OSA) is the most common primary malignant bone tumor, usually arising in the long bone...
Cancer Stem Cells (CSCs) are thought to be the cause of cancer initiation, growth and development. T...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Telangiectatic osteosarcoma (TOS) is an aggressive variant of osteosarcoma (OS) with distinctive rad...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can hal...
open10siThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program...
Osteosarcoma (OS) is the most common type of bone cancer, with a peak incidence in the early childho...
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its pathog...
Emerging evidence suggests that treatments targeting cancer stem cells (CSCs) within a tumor can hal...
open10siThis work was supported by the Plan Nacional 2008–2011 (ISC III/FEDER (Miguel Servet Program...